Allogene Therapeutics, Inc. (NASDAQ:ALLO) Insider Timothy L. Moore Sells 14,746 Shares

Allogene Therapeutics, Inc. (NASDAQ:ALLO) insider Timothy L. Moore sold 14,746 shares of Allogene Therapeutics stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total transaction of $25,215.66. Following the completion of the sale, the insider now directly owns 250,713 shares of the company’s stock, valued at $428,719.23. The trade was a 5.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Allogene Therapeutics Stock Performance

Shares of NASDAQ:ALLO opened at $1.64 on Thursday. Allogene Therapeutics, Inc. has a 1 year low of $1.61 and a 1 year high of $5.78. The stock has a 50-day simple moving average of $2.05 and a 200-day simple moving average of $2.45. The stock has a market capitalization of $343.86 million, a P/E ratio of -1.05 and a beta of 0.83.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Piper Sandler lowered their price objective on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. William Blair restated an “outperform” rating on shares of Allogene Therapeutics in a report on Thursday, November 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Allogene Therapeutics in a report on Friday, November 8th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.73.

Institutional Investors Weigh In On Allogene Therapeutics

Large investors have recently made changes to their positions in the business. Bank of New York Mellon Corp boosted its position in Allogene Therapeutics by 4.1% during the 4th quarter. Bank of New York Mellon Corp now owns 330,769 shares of the company’s stock worth $705,000 after purchasing an additional 13,150 shares during the period. Rhumbline Advisers lifted its stake in shares of Allogene Therapeutics by 10.1% during the fourth quarter. Rhumbline Advisers now owns 191,714 shares of the company’s stock worth $408,000 after purchasing an additional 17,527 shares in the last quarter. Vontobel Holding Ltd. boosted its position in shares of Allogene Therapeutics by 788.4% in the fourth quarter. Vontobel Holding Ltd. now owns 195,457 shares of the company’s stock worth $416,000 after buying an additional 173,457 shares during the period. abrdn plc acquired a new stake in shares of Allogene Therapeutics in the fourth quarter valued at about $776,000. Finally, Nordea Investment Management AB raised its holdings in shares of Allogene Therapeutics by 2.1% during the 4th quarter. Nordea Investment Management AB now owns 460,641 shares of the company’s stock valued at $986,000 after buying an additional 9,635 shares during the period. Institutional investors and hedge funds own 83.63% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).